Publication Date
| In 2026 | 0 |
| Since 2025 | 0 |
| Since 2022 (last 5 years) | 0 |
| Since 2017 (last 10 years) | 1 |
| Since 2007 (last 20 years) | 1 |
Descriptor
| Autism | 2 |
| Behavior Problems | 2 |
| Drug Therapy | 2 |
| Outcomes of Treatment | 2 |
| Pilot Projects | 2 |
| Symptoms (Individual… | 2 |
| Adolescents | 1 |
| Adults | 1 |
| Aggression | 1 |
| Attention Deficit Disorders | 1 |
| Check Lists | 1 |
| More ▼ | |
Author
| Aman, Michael G. | 1 |
| Arnold, L. Eugene | 1 |
| Benabides, Bobbie | 1 |
| Chez, Michael | 1 |
| Cook, Amelia M. | 1 |
| Hall, Kristy L. | 1 |
| Hankins, Andrea | 1 |
| Kile, Shawn | 1 |
| Lepage, Christopher | 1 |
| Parise, Carol | 1 |
| Ramadan, Yaser | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 2 |
| Reports - Research | 2 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 2 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkChez, Michael; Kile, Shawn; Lepage, Christopher; Parise, Carol; Benabides, Bobbie; Hankins, Andrea – Journal of Autism and Developmental Disorders, 2020
Prior studies have demonstrated successful irritability treatment using dopaminergic antagonists in autistic patients. The purpose of this pilot study was to assess the effect of dextromethorphan/quinidine (DM/Q) in autistic adults (18-60 years of age). This was a randomized, blinded, crossover, study of 14 patients randomized to DM/Q or a placebo…
Descriptors: Outcomes of Treatment, Randomized Controlled Trials, Pilot Projects, Drug Therapy
Atomoxetine for Hyperactivity in Autism Spectrum Disorders: Placebo-Controlled Crossover Pilot Trial
Arnold, L. Eugene; Aman, Michael G.; Cook, Amelia M.; Witwer, Andrea N.; Hall, Kristy L.; Thompson, Susan; Ramadan, Yaser – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To explore placebo-controlled efficacy and safety of atomoxetine (ATX) for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorders (ASD). Method: Children ages 5 to 15 with ASD and prominent ADHD symptoms were randomly assigned to order in a crossover of clinically titrated ATX and placebo, 6…
Descriptors: Hyperactivity, Autism, Drug Therapy, Attention Deficit Disorders
